Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMAIGTE)

Drug Name
SurVaxM Drug Info
Indication
Disease Entry ICD 11 Status REF
Glioblastoma of brain 2A00.00 Phase 2 [1]
Multiple myeloma 2A83 Phase 1 [2]
Cross-matching ID
TTD Drug ID
DMAIGTE

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Apoptosis inhibitor survivin (BIRC5) TTTPU1G BIRC5_HUMAN Inhibitor [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Apoptosis inhibitor survivin (BIRC5) DTT BIRC5 3.945 5.647 3.263 5.957
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Glioblastoma of brain
ICD Disease Classification 2A00.00
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Apoptosis inhibitor survivin (BIRC5) DTT BIRC5 1.67E-190 1.63 5.29
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT04013672) Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)